Cynata Therapeutics Limited CYYNF
Set alert
0.01 USD 0.00 0.00%
At close · Oct 30
0.11 Day range 0.11
0.0014 52-week range 0.2225
- YTD
- -95.20%
- 1 year
- -93.90%
- Open
- 0.11
- Prev close
- 0.0072
- Mkt cap
- 1.75M
- Vol
- 220
- Avg vol
- 381
- EPS
- -0.02
- P/E
- 0.00
More statistics
- Low
- 0.11
- High
- 0.11
2Y chart
Signals (22)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| RSI: Oversold | Jun 22, 2026 | 4 months ago |
| MACD: Sell Signal | Feb 20, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 5, 2025 | 11 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 17, 2025 | 11 months ago |
| MACD: Sell Signal | Aug 26, 2025 | 1 year ago |
| RSI: Overbought | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 3, 2025 | 1 year ago |
| SMA: Bearish | Jun 12, 2025 | 1 year ago |
| RSI: Oversold | Jun 12, 2025 | 1 year ago |
| MACD: Sell Signal | May 23, 2025 | 1 year ago |
| RSI: Overbought | May 5, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 28, 2025 | 1 year ago |
News
- Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript
- Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript
- Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis
- Cynata Therapeutics (OTCMKTS:CYYNF) vs. Exelixis (NASDAQ:EXEL) Financial Survey
- Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript
- Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript
- Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript
- Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
Your note
Sign in to keep a note on CYYNF — it syncs with the Stock Master app.